Albendazole

CHEMBL1483 Phase 4 Onaylandı Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
265.3 g/mol
LogP
2.9
Phase
4

A broad-spectrum antiparasitic medication used to treat a variety of worm infections including tapeworms, roundworms, and hydatid disease caused by larval tapeworm cysts. It works by preventing parasites from absorbing glucose, effectively starving them and disrupting their ability to survive and reproduce in the body.

Moleküler Ağırlık

265,3300 g/mol

LogP

2,90

TPSA

92,30 Ų

Lipinski RO5

Geçer

Terapötik Alanlar

Etki Mekanizması

Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1

InChI

InChI=1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)

Molecular Formula

C12H15N3O2S

HBD / HBA

2 / 4

Döndürülebilir Bağlar

5

Ağır Atomlar

18

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A broad-spectrum antiparasitic medication used to treat a variety of worm infections including tapeworms, roundworms, and hydatid disease caused by larval tapeworm cysts. It works by preventing parasites from absorbing glucose, effectively starving them and disrupting their ability to survive and reproduce in the body.

Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.

Yes, Albendazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1483. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 2082. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.